Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Collecting and Studying Tissue Samples From Patients With HIV-Associated Malignancies

This study is currently recruiting participants. (see Contacts and Locations)
Verified October 2014 by AIDS Malignancy Clinical Trials Consortium
Sponsor:
Collaborators:
The EMMES Corporation
Information provided by (Responsible Party):
AIDS Malignancy Clinical Trials Consortium
ClinicalTrials.gov Identifier:
NCT01567722
First received: March 29, 2012
Last updated: October 29, 2014
Last verified: October 2014
  Purpose

RATIONALE: Collecting and studying tissue samples from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.

PURPOSE: This research trial studies collecting tissue samples from patients with HIV-related malignancies.


Condition Intervention
Anal Cancer
Cervical Cancer
Lung Cancer
Lymphoma
Nonneoplastic Condition
Genetic: DNA analysis
Genetic: RNA analysis
Genetic: gene expression analysis
Genetic: polymorphism analysis
Other: biologic sample preservation procedure
Other: flow cytometry
Other: laboratory biomarker analysis
Other: medical chart review

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Tissue Acquisition for Analysis of Prognostic Factors, Immunology, and Genetic Progression of HIV-1 Associated Malignancies

Resource links provided by NLM:


Further study details as provided by AIDS Malignancy Clinical Trials Consortium:

Primary Outcome Measures:
  • Mutational spectrum of each type of HIV-1 associated malignancy [ Time Frame: Study entry (prior to chemotherapy initiation) ] [ Designated as safety issue: No ]
    Complete genomic sequencing of HIV-1 associated tumor tissue


Biospecimen Retention:   Samples With DNA

Fresh-frozen tissue, Peripheral blood mononuclear cells


Estimated Enrollment: 400
Study Start Date: July 2012
Estimated Study Completion Date: June 2015
Estimated Primary Completion Date: June 2015 (Final data collection date for primary outcome measure)
Detailed Description:

OBJECTIVES:

  • To obtain high-quality, clinically annotated tissue from patients with human immunodeficiency virus (HIV)-1 malignancy.
  • To study clinical, genetic, and immunologic parameters that have prognostic significance and/or are involved in the initiation and progression of HIV-1 malignancies, including complete genomic sequence determination of HIV-associated diffuse large B-cell lymphomas, lung cancer, anal cancer, and cervical cancer.

OUTLINE: This is a multicenter study.

Patients undergo tumor, lymph node, bone marrow, or skin biopsy, and peripheral blood mononuclear cells collection. Samples are submitted to the AIDS Malignancy Consortium (AMC) Biorepository and transferred to the AIDS and Cancer Specimen Resource (ACSR). Samples are then analyzed by the Genome Science Center of British Columbia (GSC-BC) and the HIV+ Tumor Molecular Characterization Project (HTMCP) for full genomic sequencing analysis that may include, but are not limited to, array-based gene expression profiling, comparative genome hybridization, and single nucleotide polymorphism studies by flow cytometry, cytogenetics, and molecular studies. Patients' clinical data, demographics, and treatment given are also collected prospectively in order to record treatment outcome and toxicity.

Patients are followed up at 6 months, 1 year, and 2 years for data-reporting purposes.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

HIV-infected males and females age 18 and older with one of the four malignancy types studied with available diagnostic biopsy material

Criteria

DISEASE CHARACTERISTICS:

  • Participants must have a diagnosis of a malignancy or clinical findings suggestive of a possible HIV-associated malignancy of one of four types:

    • Diffuse large B-cell lymphoma
    • Non-small cell lung malignancy
    • Anal cancer
    • Cervical cancer
  • The presence of any of the following conditions will exclude a participant from study enrollment:

    • Absence of sufficient diagnostic tumor-biopsy tissue material to meet the protocol requirements for baseline specimen submission (minimum specimen size of 10 x 10 x 2 mm); repeat tumor biopsy will not be performed solely to meet the protocol specimen-collection requirements
    • Participants whose biopsies, for the purpose of this protocol, show a diagnosis of anal intraepithelial neoplasia or cervical intraepithelial neoplasia
    • Prior treatment for the study malignancy (including neo-adjuvants), since treatment can affect the mutational spectra of tumors
  • HIV infection based on serologic documentation of HIV infection at any time prior to study entry, as evidenced by positive enzyme-linked immunosorbent assay (ELISA), positive western blot, or any other Food and Drug Administration (FDA)-approved (licensed) HIV test; alternatively, this documentation may include a record that another physician has documented that the patient has HIV based on prior ELISA and western blot, or other approved diagnostic tests

PATIENT CHARACTERISTICS:

  • Participants must be willing and able to sign an IRB-approved informed consent document

PRIOR CONCURRENT THERAPY:

  • See Disease Characteristics
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01567722

Locations
United States, California
Moores UCSD Cancer Center Recruiting
La Jolla, California, United States, 92093-0658
Contact: Clinical Trials Office - Moores UCSD Cancer Center    858-822-5354    cancercto@ucsd.edu   
Principal Investigator: William Wachsman, MD         
UCLA Clinical AIDS Research and Education (CARE) Center Suspended
Los Angeles, California, United States, 90095-1793
United States, Florida
University of Miami Recruiting
Miami, Florida, United States, 33136
Contact: Juan Carlos Ramos, MD    305-243-6611      
Principal Investigator: Juan Carlos Ramos, MD         
United States, Hawaii
Cancer Research Center of Hawaii Withdrawn
Honolulu, Hawaii, United States, 96813
United States, Illinois
John H. Stroger Hospital of Cook County Recruiting
Chicago, Illinois, United States, 60612
Contact: Erika Radeke    312-864-5204      
Principal Investigator: Paul Rubinstein, MD         
United States, Louisiana
Louisiana State University Public Hospital Recruiting
New Orleans, Louisiana, United States, 70112
Contact: Eileen Mederos    504-568-3235    emede1@lsuhsc.edu   
Principal Investigator: Thomas Reske, MD         
United States, Missouri
Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis Recruiting
Saint Louis, Missouri, United States, 63110
Contact: Lee Ratner, MD, PhD    314-362-8836    lratner@im.wustl.edu   
Principal Investigator: Lee Ratner, MD         
United States, New York
Albert Einstein Cancer Center at Albert Einstein College of Medicine Recruiting
Bronx, New York, United States, 10461
Contact: Clinical Trials Office - Albert Einstein Cancer Center at Albe    718-904-2730    aecc@aecom.yu.edu   
Principal Investigator: Missak Haigentz, MD         
Memorial Sloan Kettering Cancer Center Suspended
New York, New York, United States, 10021
United States, North Carolina
UNC Lineberger Comprehensive Cancer Center Recruiting
Chapel Hill, North Carolina, United States, 27599
Contact: Kristy Richards, MD       kristy_richards@med.unc.edu   
Principal Investigator: Kristy Richards, MD         
United States, Washington
Floyd and Delores Jones Cancer Institute at Virginia Mason Medical Center Suspended
Seattle, Washington, United States, 98111
Harborview Madison Clinic Suspended
Seattle, Washington, United States, 98104
Seattle Cancer Care Alliance Suspended
Seattle, Washington, United States, 98109
Sponsors and Collaborators
AIDS Malignancy Clinical Trials Consortium
The EMMES Corporation
Investigators
Principal Investigator: Lee Ratner, MD, PhD Washington University Siteman Cancer Center
  More Information

Additional Information:
No publications provided

Responsible Party: AIDS Malignancy Clinical Trials Consortium
ClinicalTrials.gov Identifier: NCT01567722     History of Changes
Other Study ID Numbers: AMC-083, CDR0000729843, U01CA121947
Study First Received: March 29, 2012
Last Updated: October 29, 2014
Health Authority: United States: Federal Government
United States: Institutional Review Board

Keywords provided by AIDS Malignancy Clinical Trials Consortium:
HIV infection
adult diffuse large cell lymphoma
anal cancer
cervical cancer
non-small cell lung cancer
AIDS-related diffuse large cell lymphoma

Additional relevant MeSH terms:
Anus Neoplasms
Lung Neoplasms
Lymphoma
Uterine Cervical Neoplasms
Anus Diseases
Colorectal Neoplasms
Digestive System Diseases
Digestive System Neoplasms
Gastrointestinal Diseases
Gastrointestinal Neoplasms
Genital Diseases, Female
Genital Neoplasms, Female
Immune System Diseases
Immunoproliferative Disorders
Intestinal Diseases
Intestinal Neoplasms
Lung Diseases
Lymphatic Diseases
Lymphoproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Rectal Diseases
Rectal Neoplasms
Respiratory Tract Diseases
Respiratory Tract Neoplasms
Thoracic Neoplasms
Urogenital Neoplasms
Uterine Cervical Diseases
Uterine Diseases

ClinicalTrials.gov processed this record on November 27, 2014